

**Listing of Claims**

1. (Canceled)

2. (Currently amended) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises:

- a) an amino acid sequence ~~at least 95% identical to an amino acid sequence~~ set forth as SEQ ID NO: 11;
- b) a conservative variant of the amino acid sequence set forth as SEQ ID NO: 11; *or*
- c) an immunogenic fragment comprising at least fifteen consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 11, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as SEQ ID NO: 11; *or*
- d) ~~the amino acid sequence set forth as SEQ ID NO: 11,~~

wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

3. (Previously presented) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises an amino acid sequence as set forth as SEQ ID NO:11, or a conservative variant thereof, wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

4. (Previously presented) The *P. ariasi* polypeptide of claim 3, wherein the polypeptide comprises an amino acid sequence set forth as SEQ ID NO:11.

5. (Currently amended) An antigenic-immunogenic fragment of the polypeptide of claim 4, wherein the immunogenic fragment comprises at least fifteen consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 11, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as SEQ ID NO: 11.

6 - 24. (Canceled)

25. (Currently amended) ~~A pharmaceutical~~An immunogenic composition comprising a therapeutically ~~an~~ effective amount of the polypeptide of claim 2 and a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Withdrawn and previously presented) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising:

administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

28. (Withdrawn) The method of claim 27, wherein the immune response comprises a T cell response.

29. (Withdrawn) The method of claim 27, wherein the immune response comprises a B cell response.

30. (Withdrawn) The method of claim 27, wherein the subject comprises a non-human veterinary subject.

31. (Withdrawn) The method of claim 27, wherein the subject is a dog.

32. (Withdrawn) The method of claim 27, wherein the subject is a human.

33. (Withdrawn and currently amended) The method of claim 27, wherein the polypeptide comprises ~~an amino acid sequence at least 95% identical to a~~ the amino acid sequence set forth as SEQ ID NO:11.

34. (Canceled)

35. (Withdrawn and previously presented) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.

36. (Withdrawn and currently amended) The method of claim 35, wherein the polypeptide comprises ~~an amino acid sequence at least 95% identical to a~~ the amino acid sequence set forth as SEQ ID NO: 11.

37 - 79. (Canceled)

80. (Previously presented) The polypeptide of claim 4, wherein the polypeptide consists of an amino acid sequence set forth as SEQ ID NO: 11.

81. (Currently amended) ~~A pharmaceutical~~An immunogenic composition comprising a ~~therapeutically~~an effective amount of the polypeptide of claim 3 and a pharmaceutically acceptable carrier.

82. (Withdrawn and previously presented) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

83. (Withdrawn and previously presented) The method of claim 82, wherein the immune response comprises a T cell response.

84. (Withdrawn and previously presented) The method of claim 82, wherein the immune response comprises a B cell response.

85. (Withdrawn and previously presented) The method of claim 82, wherein the subject comprises a non-human veterinary subject.

86. (Withdrawn and previously presented) The method of claim 82, wherein the subject is a dog.

87. (Withdrawn and previously presented) The method of claim 82, wherein the subject is a human.

88. (Withdrawn and previously presented) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.